Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TV investigations linked to increased adverse drug reports
Research published in the British Journal of Clinical Pharmacology shows a sudden increase in reports immediately after each of the three programs were aired in the UK in
Research published in the British Journal of Clinical Pharmacology shows a sudden increase in reports immediately after each of the three programs were aired in the UK in
The committee voted eight to seven in favor of adding the warning to ADHD medications despite recognizing that the data suggests that incidence rates of rare serious cardiovascular
Although widely used for quick relief of congestive heart failure (CHF) symptoms – cough, shortness of breath and swelling in the feet, legs and ankles – up until
The trial has been temporarily suspended to allow a data safety monitoring board (DSMB) to conduct a review of 60-day safety data. Suspension of the trial was recommended
The AstraZeneca-supported study, which was published in the February issue of Mayo Clinic Proceedings, looked at 3,575 people. Of the 2,211 respondents who reported pain of more than
The drug candidate, a synthetic, peptide-based, next-generation erythropoiesis-stimulating agent (ESA), is designed to stimulate the production of red blood cells. It is currently being evaluated in four phase
According to Dr Sandra Horning of the Eastern Cooperative Oncology Group, the drug is the first to significantly improve survival for patients with this form of non-Hodgkin’s lymphoma
In the trial 140 patients were randomized to receive either VLTS 934 or a saline placebo. The primary endpoint of the trial is improvement in exercise tolerance 90
In a human phase I trial, AQ13 was shown to be well tolerated and preclinical analysis indicates that AQ13 is highly active against Plasmodium falciparum, the most severe
Schering will now take over the development of the product candidate. There are no milestone payments associated with the option exercise, however, if Schering successfully develops the product